Cost-Effectiveness of Aprepitant in Egyptian Patients Receiving Highly Emetogenic Therapy from the Third Party Payer Perspective
Nov 1, 2014, 00:00
10.1016/j.jval.2014.08.2272
https://www.valueinhealthjournal.com/article/S1098-3015(14)04202-8/fulltext
Title :
Cost-Effectiveness of Aprepitant in Egyptian Patients Receiving Highly Emetogenic Therapy from the Third Party Payer Perspective
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(14)04202-8&doi=10.1016/j.jval.2014.08.2272
First page :
A634
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
1733